BioSpace News Archive

Drug Development

Pathalys Pharma Announces Phase 3 Program for Upacicalcet

Pathalys Pharma, Inc. today announced plans for a phase 3 program to support the application of upacicalcet (designated PLS240 for clinical trials), globally.

April 7, 2022
·
3 min read
Biotech Bay

Harpoon Therapeutics to Participate in Canaccord Genuity Horizons in Oncology Virtual Conference

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing novel T cell engagers, announced that management will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Virtual Conference.

April 7, 2022
·
1 min read
Pharm Country

Agile Therapeutics® Announces Poster Presentation at the 2022 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists (ACOG)

Agile Therapeutics, Inc. will be presented at the 2022 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting.

April 7, 2022
·
4 min read
Pharm Country

Verrica Pharmaceuticals Announces Participation in the 21st Annual Needham Virtual Healthcare Conference

Verrica Pharmaceuticals Inc. today announced that Ted White, Verrica President and CEO, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022 at 3:00 p.m. ET.

April 7, 2022
·
1 min read
Deals

Claritas Announces Approval from OTC to Up-List to OTCQB

Claritas Pharmaceuticals, Inc. is pleased to announce that it has obtained approval from the OTC Markets Group for listing of its Common Shares on the OTCQB.

April 7, 2022
·
3 min read
Pharm Country

Biohaven Presentation at AAN Showed Decreased Opioid Use in Migraine Patients Following Nurtec® ODT Therapy: A Real-World Administrative Claims Analysis

Biohaven announced the presentation of important findings pertaining to the benefit of Nurtec® ODT (rimegepant) in decreasing the burden of opioid use among a significant number of migraine patients in real world clinical practice.

April 7, 2022
·
7 min read
Lone Star Bio

Natera Publishes VALID Study Results for Prospera Lung dd-cfDNA Transplant Rejection Assessment Test

Natera, Inc. today announced the publication of the VALID study, showcasing its Prospera™ Lung donor-derived cell-free DNA (dd-cfDNA) test in assessing rejection and allograft injury in lung transplant patients.

April 7, 2022
·
4 min read
Drug Development

Stoke Therapeutics to Present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

Stoke Therapeutics, Inc. announced today the upcoming presentation of new preclinical data on STK-002 at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting being held May 1-4, 2022 in Denver, Colorado.

April 7, 2022
·
4 min read
Business

Navidea Biopharmaceuticals Announces New Senior Regulatory Consultant and Return of Former Director of Regulatory Affairs

Navidea Biopharmaceuticals, Inc. today welcomed Kenneth Berger, Ph.D., as Senior Regulatory Consultant, and the return of the Company’s former Director of Regulatory Affairs, Richard McFerron.

April 7, 2022
·
5 min read
Drug Development

REDCLOUD BIO TO PRESENT PRECLINICAL DATA OF NEXT-GENERATION EGFR TKI H002 AT ANNUAL MEETING OF AMERICAN ASSOCIATION OF CANCER RESEARCH

RedCloud Bio announced the upcoming presentation of preclinical data of H002, a next-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in non-small lung cancer (NSCLC).

April 7, 2022
·
3 min read